(R)-Glycidylphthalimide (CAS No. 181140-34-1) Market (2026): Market Leaders Driving Global Pharmaceutical Innovation

MARKET INSIGHTS

Global (R)-Glycidylphthalimide (CAS No. 181140-34-1) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(R)-Glycidylphthalimide is a chiral epoxide compound bearing a phthalimide protecting group, widely recognized as a versatile and high‑value building block in asymmetric synthesis and pharmaceutical chemistry. Its molecular structure enables selective ring‑opening reactions, making it particularly valuable in the synthesis of enantiomerically pure intermediates used across active pharmaceutical ingredient (API) development, agrochemical formulations, and advanced specialty chemical manufacturing.

The market is witnessing steady growth driven by the expanding demand for chiral intermediates in drug discovery and the increasing adoption of asymmetric synthesis methodologies by pharmaceutical manufacturers worldwide. The compound’s role in producing optically active amino alcohols and other stereochemically defined structures has reinforced its relevance as fine chemical pipelines grow more sophisticated. Key suppliers operating in this space include TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar, among other specialty chemical producers maintaining dedicated chiral building block portfolios.

(R)-Glycidylphthalimide (CAS No. 181140-34-1) Market – View in Detailed Research Report

🔟 1. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: High‑purity chiral epoxides, API intermediates, custom synthesis services

Merck’s MilliporeSigma division dominates the fine‑chemical segment with a robust global production footprint. The company’s focus on advanced asymmetric synthesis and stringent quality controls positions it as a preferred partner for pharmaceutical developers seeking enantiomerically pure building blocks.

Sustainability Initiatives: Integrated green chemistry programs, waste‑minimization protocols, and renewable feedstock sourcing.

• Dedicated R&D budget exceeding USD 200 million for chiral chemistry.
• Partnerships with leading biopharma firms to co‑develop next‑generation APIs.
• Continuous improvement of process yield to reduce energy consumption.

9️⃣ 2. Tokyo Chemical Industry Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: Advanced asymmetric synthesis technologies, industrial‑grade chiral epoxides, CDMO services

TCI leverages its strong Asian manufacturing base to deliver high‑purity intermediates at scale. The firm’s investment in continuous‑flow reactors enhances throughput while maintaining enantiomeric excess above 99%.

Sustainability Initiatives: Adoption of enzymatic resolution processes, carbon‑neutral manufacturing targets.

• Expanded GMP facilities across Japan, China, and India.
• Collaborations with academic institutions on catalyst development.
• Implementation of digital process analytics for real‑time quality assurance.

8️⃣ 3. Thermo Fisher Scientific

Headquarters: Waltham, USA
Key Offering: Alfa Aesar catalog of specialty chemicals, custom synthesis, supply‑chain integration

Thermo Fisher’s strategic positioning within the global chemical distribution network allows it to serve both research and industrial customers efficiently. Its focus on high‑purity chiral intermediates supports complex drug‑development projects.

Sustainability Initiatives: Investment in process analytical technology, reduction of solvent usage.

• Integrated logistics platform for just‑in‑time delivery.
• Partnerships with CDMOs to accelerate API development.
• Continuous monitoring of environmental impact metrics.

7️⃣ 4. Hairui Fine Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Cost‑efficient chiral epoxide production, GMP‑compliant facilities, custom synthesis

Hairui’s rapid expansion of continuous‑flow reactors and GMP infrastructure has enabled it to capture a growing share of the generic API market, offering competitive pricing without compromising purity.

Sustainability Initiatives: Adoption of green solvents, waste‑reduction programs.

• Strategic investment in renewable feedstocks.
• Collaboration with local universities on catalyst research.
• Implementation of ISO 14001 environmental management system.

6️⃣ 5. Capot Chemical Co., Ltd.

Headquarters: Shenzhen, China
Key Offering: Custom chiral intermediates, rapid‑turnaround synthesis, CDMO services

Capot’s focus on rapid synthesis and flexible contract manufacturing has positioned it as a go‑to partner for emerging biopharma companies needing timely supply of chiral building blocks.

Sustainability Initiatives: Energy‑efficient manufacturing, water‑recycling systems.

• Expansion of GMP‑grade production lines.
• Partnerships with global CDMOs for scale‑up projects.
• Investment in renewable energy for manufacturing sites.

5️⃣ 6. Biosynth AG

Headquarters: Bern, Switzerland
Key Offering: Catalog‑scale chiral synthesis, library development, biotech support

Biosynth’s expertise in library synthesis for drug discovery has made it a preferred supplier for biotech firms seeking diverse chiral scaffolds.

Sustainability Initiatives: Eco‑friendly process design, carbon‑offset programs.

• Development of biocatalytic routes for epoxide synthesis.
• Collaboration with EU research consortia on green chemistry.
• Implementation of life‑cycle assessment for new products.

4️⃣ 7. Enamine Ltd.

Headquarters: Kyiv, Ukraine
Key Offering: Library synthesis, chiral building blocks, academic collaborations

Enamine’s focus on synthetic libraries has positioned it as a key partner for academic and industrial research in drug discovery.

Sustainability Initiatives: Reduction of hazardous waste, adoption of green solvents.

• Partnerships with universities for catalyst development.
• Investment in green chemistry training programs.
• Continuous improvement of process safety protocols.

3️⃣ 8. Ambeed Inc.

Headquarters: Toronto, Canada
Key Offering: High‑purity chiral intermediates, custom synthesis, API support

Ambeed’s emphasis on quality and regulatory compliance makes it a trusted supplier for North American pharmaceutical developers.

Sustainability Initiatives: Energy‑efficient manufacturing, waste‑minimization.

• Expansion of cGMP facilities in Canada.
• Collaboration with Canadian universities on chiral catalyst research.
• Implementation of ISO 50001 energy management system.

2️⃣ 9. JRD Fluorochemicals Ltd.

Headquarters: Hyderabad, India
Key Offering: Fluorinated chiral intermediates, custom synthesis, cost‑effective production

JRD Fluorochemicals leverages its expertise in fluorinated chemistry to offer unique chiral epoxides with enhanced pharmacokinetic properties.

Sustainability Initiatives: Renewable energy usage, solvent‑recycling programs.

• Investment in renewable energy for manufacturing sites.
• Partnerships with Indian research institutes on green fluorination.
• Implementation of ISO 14001 environmental management system.

1️⃣ 10. Oakwood Products, Inc.

Headquarters: Baltimore, USA
Key Offering: High‑purity specialty chemicals, custom synthesis, rapid delivery

Oakwood’s focus on niche specialty chemicals and rapid turnaround services serves a diverse portfolio of pharmaceutical and material science customers.

Sustainability Initiatives: Green chemistry protocols, waste‑reduction initiatives.

• Expansion of specialty chemical production lines.
• Collaboration with industry consortia on green manufacturing.
• Continuous improvement of supply‑chain sustainability.

Download FREE Sample Report

Get Full Report

📈 Outlook

The (R)-Glycidylphthalimide market is set to sustain its upward trajectory as pharmaceutical developers continue to prioritize enantiomerically pure intermediates. The convergence of advanced asymmetric synthesis, digital process analytics, and green chemistry principles is expected to streamline production, reduce costs, and enhance regulatory compliance. These dynamics position the market for continued expansion, particularly in oncology, CNS, and rare‑disease segments where chiral purity drives therapeutic differentiation.

🔮 Future Trends

• Broad adoption of continuous‑flow and biocatalytic routes, lowering production costs and improving yield.
• Increased focus on bio‑based feedstocks and renewable solvents to meet ESG mandates.
• Expansion of custom synthesis capabilities to support rapid‑turnaround drug‑development projects.
• Growth in regional manufacturing hubs, especially in Asia‑Pacific, to reduce supply‑chain exposure.
• Emergence of digital twins and AI‑driven process optimization to accelerate scale‑up.